Thomas A. Harlan, CEO of Emergent Technologies, Inc. and Dr. William Hildebrand, Chief Scientist at Pure MHC and Research Professor in the OU Department of Microbiology and Immunology, co-founded Pure MHC to leverage the sHLA platform technology of Pure Protein in the discovery of HLA Class I and Class II peptide targets for use immunotherapies to cancer, infectious disease, and autoimmune diseases.